Background: The CARD study demonstrated superiority of cabazitaxel over abiraterone/enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) who received prior docetaxel and progressed ≤12 months on the alternative androgen-receptor-targeted agent (ARTA). The objective was to compare characteristics and treatment patterns of patients from a real-world dataset with the CARD population. Methods: Real-world data were collected from Medimix Live TrackerTM, a retrospective, global oncology database of healthcare professional-reported electronic patient medical forms (2001–2019), with data from patients from Europe, USA, Brazil and Japan. The database contained patient, tumor and treatment information for 12,140 patients who received ≥1 line of treatment for mCRPC. A CARD-like cohort included patients treated with docetaxel, prior abiraterone/enzalutamide and cabazitaxel. Results: A large proportion of patients received ≥2 lines of ARTA (35.1%) with 42% of patients who received a first-line ARTA receiving another ARTA in second line. Of the total patients, 452 were eligible for the CARD-like cohort. Median age of the CARD-like cohort was comparable to CARD (73 vs 70 years). The CARD-like cohort had unfavorable disease characteristics vs CARD: ECOG PS ≥ 2 (45% vs 4.7%); metastasis at diagnosis (46% vs 38%) and Gleason 8–10 (65% vs 57%). More patients in the CARD-like cohort received ARTA before docetaxel (48% vs 39%) and received the first ARTA for >12 months (30% vs 17%) compared with CARD. Despite more patients in the CARD-like cohort receiving the lower 20 mg/m2 dose of cabazitaxel (55% vs 21%), cabazitaxel treatment duration was similar (21.9 vs 22.0 weeks). Conclusions: Sequential use of ARTA was frequent. Results indicate the CARD population is reflective of routine clinical practice and duration of response to cabazitaxel was similar in a real-world population.
Bibliographical noteFunding Information:
RdW has provided a consulting or advisory role for Sanofi, Merck Sharp & Dohme, Roche/Genetech, Janssen, Bayer and Clovis Oncology, and received travel/ accommodation/expenses from Lilly. RdW has received honoraria and/or research funding from Sanofi, Merck Sharp & Dohme and Bayer. SF received research funding from Pfizer and received personal fees from Pfizer, Astellas, Janssen, Bayer, Myovant, AstraZeneca, Merck, Dendreon and Sanofi. SO received honoraria from Pfizer, Bayer, Novartis, BMS, Merck, Janssen and Astellas, and received travel/accommodation/ expenses from Pfizer, Bayer, Novartis, BMS, Merck, Janssen, Astellas and Sanofi. GM has received personal fees (contracted by Sanofi) from Sanofi. PC has received fees (contracted by Sanofi) from Sanofi and is employed by Medimix. AC has received fees (contracted by Sanofi) from Sanofi and as a data provider for Medimix. RP is employed by Sanofi and AO is a former employee of Sanofi. AO owns stock in Sanofi. AM has received personal fees from Janssen, Astellas, Seattle Genetics and Genentech, and received personal fees and research funding from Bayer.
This study was funded by Sanofi. The authors would like to thank Henry Gazay for the creation of the LiveTracker and assistance in the data collection. The authors would like to thank Raphael Ognar for overseeing the chart collection. The authors received editorial support from Danielle Walsh and Amber Wood of MediTech Media, funded by Sanofi.
© 2022, The Author(s).